Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 12/20 | 0.55 |
| ▸ | PNP | P00491 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | POLG | P54098 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12800326 | 0.94 | HPRT1 (0.57) | HPRT1PNPPOLBPOLA1POLG | |
| SCHEMBL12732296 | 0.88 | PNP (0.51) | HPRT1PNPPOLBPOLA1POLG | |
| SCHEMBL12732295 | 0.87 | HPRT1 (0.57) | HPRT1PNPPOLB | |
| SCHEMBL7196190 | 0.87 | HPRT1 (0.58) | HPRT1PNPPOLBPOLA1POLG | |
| Penciclovir Triphosphate SCHEMBL30945294 | 0.86 | POLG (0.65) | HPRT1PNPPOLBPOLA1POLG | |
| Penciclovir Triphosphate SCHEMBL1664402 | 0.86 | POLG (0.65) | HPRT1PNPPOLBPOLA1POLG | |
| Ammonia Solution, Strong SCHEMBL5930250 | 0.86 | HPRT1 (0.57) | HPRT1PNPPOLBPOLA1POLG | |
| SCHEMBL9824169 | 0.84 | HPRT1 (0.60) | HPRT1PNP | |
| Penciclovir SCHEMBL454090 | 0.84 | HPRT1 (0.66) | HPRT1PNP | |
| Penciclovir SCHEMBL4240104 | 0.84 | HPRT1 (0.66) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS AG (CH) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281470-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | HPRT1 3/4885PNP 2/4885POLB 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.